The consortium has worked with Vidiia to deliver a market leading product, critical in offering fast and accurate point of care necessary against the fight against COVID-19. The new and innovative SARS-CoV-2 rapid point of care diagnostics platform relies on a reverse-transcription loop-mediated isothermal amplification (RT-LAMP) and a hand-held smart diagnostic device to provide highly specific 96.8% and highly sensitive 98.6% results for up to six patients simultaneously in 20 minutes.

Vidiia Ltd is a spin-out medical technology company, formed in June 2020 to lead and drive the commercial success of the innovative Virus Hunter 6 (VH6). The VH6 is a rapid diagnostic LAMP testing platform targeting SARS-CoV-2, created successfully in collaboration with our consortium including Surrey University, Brunel University London and Lancaster.